HD Focus

Krakow, Poland | October 22–24, 2026

<p>The post Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease first appeared on Huntington's Disease Society of America.</p>

One year into treatment, SKY-0515 continues to lower huntingtin and shows encouraging trends with signs and symptoms of HD. A larger trial is enrolling to determine whether the drug truly slows HD progression

Um ano após o início do tratamento, o medicamento experimental segue demonstrando melhora clínica, redução da huntingtina mutante e de proteína associada à expansão da doença. Estudo maior está em fase de recrutamento.

O post Skyhawk apresenta resultados de Fase 1/2 do SKY-0515 após doze meses de estudo apareceu primeiro em ABH – Associação Brasil Huntington.

For Huntington’s Disease Awareness Month, Eddie’s story is one of fierce love, resilience, and determination – not just to care […]

⏱️8 min read | May 2026: 2 year data from the votoplam trial suggests disease progression may slow; AMT-130 heads to the UK for regulatory review; pigs reveal immune cells invading the HD brain; and new science zooms in on toxic huntingtin fragments.

Comissão mantém parecer desfavorável à inclusão do medicamento no sistema público de saúde fundamentando a decisão no alto impacto orçamentário e na incerteza do benefício clínico em longo prazo.

O post Conitec rejeita incorporação da deutetrabenazina para doença de Huntington no SUS apareceu primeiro em ABH – Associação Brasil Huntington.

Francophone Youth Day – Written by the Moving Forward team on 27th May 2026 On April 25, the Association Huntington France (AHF) hosted its first Francophone…

Raising Huntington’s Disease Awareness: Beyond the Month of May As May draws to a close and Huntington’s Disease (HD) Awareness Month ends, advocates are urging the public to continue the fight for awareness and support year-round. For those who do not know, Huntington’s Disease—a rare, inherited neurodegenerative disorder—affects thousands of families across the United States, yet remains widely misunderstood. Organizations like Help 4 HD International are leading the charge to keep HD in...

⏱️7 min read | In a recent paper, scientists targeted a small, harmful piece of the huntingtin message (HTT1a) in HD mice. This reduced toxic protein clumps and delayed genetic changes, more than targeting full length HTT.

NAARDEN, The Netherlands & WALTHAM, Mass. — May 26, 2026 — Prilenia Therapeutics B.V. today announced a Data Use Agreement (DUA) under which Prilenia will provide CHDI with clinical data from the placebo arms of its PRIDE and PROOF studies for the purpose of advancing research into treatments for Huntington’s disease (HD).

HD治療薬についての臨床試験の進捗状況を更新しました。欧米の製薬会社４社からの公表情報をもとに取りまとめました。 こちら

ATTENZIONE POSSIBILITA’ DI ERRORI Per garantire una diffusione rapida e capillare delle notizie relative alla ricerca sull’HD e agli aggiornamenti sulle sperimentazioni in corso, questo articolo è stato sintetizzato tramite Intelligenza Artificiale e non è stato  revisionato da un redattore umano. Per una consultazione più affidabile, si consiglia di fare riferimento alle versioni originale in […]

L'articolo Pridopidina: ritirata la domanda di approvazione europea per la malattia di Huntington sembra essere il primo su corea di huntington -AICH ROMA ONLUS -.

2026年7月4日（土）13：30～17：00　東京駅周辺の会議室にて。詳細は4月発行の会報にてお知らせします。お問合せは事務局メール　jhdn2000（アットマーク）jhdn.org ※アットマークを@に変更してくださ […]

⏱️ 5 min read | A recent study suggests that strengthening the brain’s own clean-up system could slow Huntington’s disease.

SWEDISH ONLINE SESSION – att testa sig – Written by the Moving Forward team on 19th May 2026 On Tuesday, May 5, a webinar was held…

aktualizácia 19.5.2026 Žiadosť o schválenie Pridopidínu bola stiahnutá. EMA vyhodnotila liek vo všetkých skupinách ako nedostatočne efektívny. A Spoločnosť Prelinea stiahla svoju žiadosť.  Originál článku tu. aktualizácia 2.3..2026 Pridopidín v kombinácii s HA10 znížil stratu neurónov buniek až o 74% Originál článku tu. aktualizácia z 17.10.2025 Podľa dvojročných výsledkov Pridopidín spomaľuje progres ochorenia u ľudí ktorý neužívajú …

Pridopidin Čítajte viac »